Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Jupiter Neurosciences (JUNS) Shares Outstanding (2024 - 2025)

Jupiter Neurosciences (JUNS) has disclosed Shares Outstanding for 2 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.06% to $34.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.4 million through Dec 2025, up 4.06% year-over-year, with the annual reading at $34.4 million for FY2025, 4.06% up from the prior year.
  • Shares Outstanding for Q4 2025 was $34.4 million at Jupiter Neurosciences, roughly flat from $34.3 million in the prior quarter.
  • The five-year high for Shares Outstanding was $34.8 million in Q2 2025, with the low at $26.5 million in Q1 2024.